Nonetheless, the exquisite ability of A2AR blockade to restore the defective A/C CA3 LTP in APP/PS1 mice, in parallel to studies linking A2AR to cognitive deficits11, 12, provides an additional mechanistic support to encourage testing the therapeutic efficacy of A2AR antagonists in early AD patients. The gene discussed is ADORA2A; the disease is Alzheimer disease.